Paul Hastings LLP advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in connection with the pricing of ProKidney Corp.’s (Nasdaq: PROK) upsized public offering and concurrent registered direct offering. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions.

Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi led the Paul Hastings team, which also included Securities and Capital Markets partner Will Magioncalda and associates Chris Guerin and Adam Swank.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.